GCP
DMAC icon

GSA Capital Partners’s DiaMedica Therapeutics DMAC Stock Holding History

GSA Capital Partners’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$511K Buy
72,565
+14,043
+24% +$86.3K 0.03% 991
2026
Q1 		$396K Buy
58,522
+44,658
+322% +$354K 0.02% 1068
2025
Q4 		$110K Buy
+13,864
New +$104K 0.01% 1517

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

GSA Capital Partners's DMAC Position: Q2 2026 in Review

GSA Capital Partners increased its DiaMedica Therapeutics (DMAC) stake by 24% in Q2 2026, buying an estimated $86.3K and bringing the position to 72,565 shares worth $511K. The position accounts for 0.03% of the portfolio, ranked #991.

GSA Capital Partners first reported a position in DMAC in Q4 2025 and has held it in 3 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • GSA Capital Partners held 72,565 shares of DiaMedica Therapeutics worth $511K as of Q2 2026.
  • GSA Capital Partners bought 14,043 DiaMedica Therapeutics shares in Q2 2026, an estimated $86.3K.
  • DiaMedica Therapeutics made up 0.03% of GSA Capital Partners's portfolio in Q2 2026, its #991 holding.
  • GSA Capital Partners first reported a position in DiaMedica Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.